HUT72599A - Pharmaceutical compositions against hyperglychemia - Google Patents

Pharmaceutical compositions against hyperglychemia

Info

Publication number
HUT72599A
HUT72599A HU9501900A HU9501900A HUT72599A HU T72599 A HUT72599 A HU T72599A HU 9501900 A HU9501900 A HU 9501900A HU 9501900 A HU9501900 A HU 9501900A HU T72599 A HUT72599 A HU T72599A
Authority
HU
Hungary
Prior art keywords
hyperglychemia
pharmaceutical compositions
compositions against
prepn
antihyperglycaemically
Prior art date
Application number
HU9501900A
Other languages
English (en)
Other versions
HU9501900D0 (en
HU226946B1 (en
Inventor
Reinhard Brueckner
Elbert Kaan
Dieter Ziegler
Original Assignee
Kali Chemie Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kali Chemie Pharma Gmbh filed Critical Kali Chemie Pharma Gmbh
Publication of HU9501900D0 publication Critical patent/HU9501900D0/hu
Publication of HUT72599A publication Critical patent/HUT72599A/hu
Publication of HU226946B1 publication Critical patent/HU226946B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Fats And Perfumes (AREA)
HU9501900A 1994-07-01 1995-06-28 Pharmaceutical compositions against hyperglychemia HU226946B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4423177A DE4423177A1 (de) 1994-07-01 1994-07-01 Antihyperglykämisch wirksame Arzneimittel

Publications (3)

Publication Number Publication Date
HU9501900D0 HU9501900D0 (en) 1995-08-28
HUT72599A true HUT72599A (en) 1996-05-28
HU226946B1 HU226946B1 (en) 2010-03-29

Family

ID=6522064

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9501900A HU226946B1 (en) 1994-07-01 1995-06-28 Pharmaceutical compositions against hyperglychemia

Country Status (23)

Country Link
US (1) US5712283A (hu)
EP (1) EP0689837B1 (hu)
JP (1) JP3841846B2 (hu)
KR (1) KR100366130B1 (hu)
CN (1) CN1092961C (hu)
AT (1) ATE210444T1 (hu)
AU (1) AU691580B2 (hu)
CA (1) CA2152998C (hu)
CZ (1) CZ287563B6 (hu)
DE (2) DE4423177A1 (hu)
DK (1) DK0689837T3 (hu)
DZ (1) DZ1894A1 (hu)
ES (1) ES2167385T3 (hu)
FI (1) FI117374B (hu)
HU (1) HU226946B1 (hu)
IL (1) IL113411A (hu)
NO (1) NO307029B1 (hu)
NZ (1) NZ270990A (hu)
PT (1) PT689837E (hu)
RU (1) RU2145857C1 (hu)
SK (1) SK282227B6 (hu)
UA (1) UA27954C2 (hu)
ZA (1) ZA954691B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4941796A (en) * 1995-02-28 1996-09-18 Beiersdorf-Lilly Gmbh Use of moxonidine for the treatment of atherosclerosis
KR20000016406A (ko) * 1996-06-06 2000-03-25 피터 지. 스트링거 울혈성 심장 마비 치료용 제제 및 방법_
NO980546L (no) * 1997-02-11 1998-08-12 Lilly Co Eli Farmas°ytiske midler
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
ZA989251B (en) * 1997-10-17 2000-04-10 Lilly Co Eli Potentiation of pharmaceuticals.
US6897019B1 (en) 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
WO2000044355A1 (en) * 1999-01-29 2000-08-03 Eli Lilly And Company Moxonidine salts
PL195124B1 (pl) * 1999-02-01 2007-08-31 Solvay Pharm Gmbh Nowe zastosowanie moksonidyny
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
RU2219930C2 (ru) * 2001-09-24 2003-12-27 Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Способ лечения заболеваний печени
CA2487541A1 (en) * 2002-06-19 2003-12-31 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
PL1673107T3 (pl) * 2003-10-10 2008-06-30 Abbott Laboratories Gmbh Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II
RU2426543C1 (ru) * 2010-05-24 2011-08-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН НИИ фармакологии СО РАМН Способ дифференцированного назначения моксонидина у пациентов с артериальной гипертензией на фоне метаболического синдрома
RU2542462C2 (ru) * 2013-06-28 2015-02-20 Андрей Владиславович Струтынский Способ коррекции кризового течения гипертонической болезни и абдоминального ожирения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
US5712283A (en) 1998-01-27
ZA954691B (en) 1996-01-29
JPH0840906A (ja) 1996-02-13
SK74995A3 (en) 1996-05-08
CZ287563B6 (en) 2000-12-13
DZ1894A1 (fr) 2002-02-17
ES2167385T3 (es) 2002-05-16
JP3841846B2 (ja) 2006-11-08
DE59509928D1 (de) 2002-01-24
SK282227B6 (sk) 2001-12-03
CN1122224A (zh) 1996-05-15
IL113411A (en) 1999-07-14
RU2145857C1 (ru) 2000-02-27
KR100366130B1 (ko) 2003-03-26
CZ139395A3 (en) 1996-01-17
EP0689837B1 (de) 2001-12-12
CA2152998C (en) 2002-09-03
IL113411A0 (en) 1995-07-31
CN1092961C (zh) 2002-10-23
NZ270990A (en) 1997-06-24
FI117374B (fi) 2006-09-29
ATE210444T1 (de) 2001-12-15
NO307029B1 (no) 2000-01-31
UA27954C2 (uk) 2000-10-16
KR960003729A (ko) 1996-02-23
EP0689837A2 (de) 1996-01-03
DK0689837T3 (da) 2002-03-11
EP0689837A3 (de) 1996-06-05
AU691580B2 (en) 1998-05-21
HU9501900D0 (en) 1995-08-28
NO952624D0 (no) 1995-06-30
AU1775795A (en) 1996-01-18
NO952624L (no) 1996-01-02
HU226946B1 (en) 2010-03-29
DE4423177A1 (de) 1996-01-04
CA2152998A1 (en) 1996-01-02
PT689837E (pt) 2002-04-29
FI953256A0 (fi) 1995-06-30
FI953256L (fi) 1996-01-02

Similar Documents

Publication Publication Date Title
HUT72599A (en) Pharmaceutical compositions against hyperglychemia
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
GR3004482T3 (hu)
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
CA2148194A1 (en) Cyclopeptides of the formula i
AU2101492A (en) Methanoanthracenes having antidopaminergic activity
TW222265B (hu)
DE58906387D1 (de) Verwendung von Benzimidazolen zur Herstellung eines Arzneimittels mit antiischämischen Wirkungen am Herzen und dessen Kombinationen mit Beta-Blockern oder Bradycardica.
ATE127343T1 (de) Pharmazeutische zubereitung von roxindol oder carmoxirol mit vorgeqüollener stärke.
NZ238022A (en) Indole derivatives and pharmaceutical compositions
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
TW222622B (hu)
EP0471388A3 (de) Mittel zur Behandlung der Herzinsuffizienz
GR861646B (en) 4-amino-2-(imidazolidin-2-on-1-yl)-pyrimidino-5-carbonic acid -(n-triphthoro - methyl-phenyl)-amides for antithrombotic protection and treatment use and preparation of antithrombotically active medicines
ES2117114T3 (es) Nuevos derivados de tiaxolidin-diona, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ATE116296T1 (de) Säureadditionssalze einer optisch aktiven alaninanilidverbindung und diese enthaltende, pharmazeutische zusammensetzungen.
JPS6434920A (en) Therapy for mycobacterium abium intracellular complex infection
ZA921091B (en) Substituted benzofuranylpiperidine as a nootropic agent
PH30180A (en) Leustroducsin h its preparation and its therapeutic use
IT1245390B (it) Composizione farmaceutica ad attivita' antivirale
PT82535B (en) Pharmacologically active propionylanilides

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ABBOTT PRODUCTS GMBH, DE

Free format text: FORMER OWNER(S): KALI CHEMIE PHARMA GMBH., DE; SOLVAY PHARMACEUTICALS GMBH, DE

MM4A Lapse of definitive patent protection due to non-payment of fees